India to Iraq: Amikacin Export Trade Route

To import Amikacin formulations into Iraq, the following approvals and registrations are necessary:

• Product Registration: All pharmaceutical products, including Amikacin formulations, must be registered with the IDRA. The registration process involves submitting a comprehensive dossier demonstrating the product's safety, efficacy, and quality.

• Dossier Format: The required dossier format aligns with the Common Technical Document (CTD) structure, encompassing modules on administrative information, quality, non-clinical, and clinical data.

• Approval Timelines: The approval process duration can vary; however, new chemical entities (NCEs) are typically prioritized, followed by generics and other formulations.

• Registration Validity: For imported products, the registration is valid for five years and is renewable upon submission of updated data.

• Product Registration Fees: Specific fees associated with product registration are determined by the IDRA and may vary based on the product category and complexity.

• GMP Inspection Requirements: The MOH mandates the right to conduct inspections to ensure Good Manufacturing Practice (GMP) compliance if deemed necessary.

Indian manufacturers exporting Amikacin formulations to Iraq must comply with the following quality and GMP standards:

• GMP Certification: Manufacturers are required to adhere to WHO GMP standards.

• Approved Indian Facilities: As of March 2026, several Indian pharmaceutical companies have been approved by the Iraqi MOH for supplying medicines, including Amikacin formulations.

• Recent Inspections and Regulatory Actions: The IDRA reserves the right to conduct inspections to ensure GMP compliance.

In the past 18 months, several regulatory developments have impacted Indian pharmaceutical exports to Iraq:

• Custom Duties Reduction: On July 24, 2019, the Council of Ministers issued Order No. 255, reducing customs duties on imported medicines and medical appliances from 10% to 0.5%.

• Quality Control Enhancements: In response to global concerns over pharmaceutical quality, the IDRA has intensified its focus on GMP compliance and quality assurance measures.

These developments underscore Iraq's commitment to ensuring the quality and safety of imported pharmaceutical products, including Amikacin formulations.

Amikacin, an aminoglycoside antibiotic, is primarily used to treat severe bacterial infections. In Iraq, the demand for Amikacin formulations is influenced by factors such as the prevalence of bacterial infections, healthcare infrastructure, and public health initiatives. While specific market size data for Amikacin in Iraq for 2024-2025 is not readily available, the country's healthcare sector has been experiencing growth, leading to increased demand for essential antibiotics. Iraq relies heavily on imports for its pharmaceutical needs, including Amikacin formulations, due to limited domestic manufacturing capabilities.

Iraq maintains a 0% import duty on pharmaceutical products classified under HS code 30049099, which includes finished Amikacin formulations. This exemption is part of Iraq's policy to facilitate access to essential medicines. Additionally, there are no value-added taxes (VAT) or goods and services taxes (GST) imposed on pharmaceutical imports. Currently, there are no free trade agreements (FTAs) between India and Iraq that specifically affect pharmaceutical tariffs, nor are there any anti-dumping duties imposed on Amikacin imports from India.

India is a major supplier of Amikacin formulations to Iraq, accounting for 23.2% of India's total Amikacin formulation exports, valued at $4.9 million USD across 101 shipments from 35 Indian manufacturers/exporters. The top Indian exporters include AJANTA PHARMA LIMITED ($1.0M), LYKA LABS LIMITED ($0.9M), and BRAWN LABORATORIES LIMITED ($0.7M). The primary buyers in Iraq are AL NIMAA SCIENTIFIC BUREAU ($0.9M), Hawkary Pharmaceutical Co. ($0.6M), and IBN SINA SCIENTIFIC BUREAU ($0.4M). While specific data on other countries supplying Amikacin to Iraq is limited, India's competitive pricing and established trade relationships position it as a key player in the Iraqi market. Comparative pricing data between India and competitors like China or European Union manufacturers is not readily available, but India's pharmaceutical industry is known for its cost-effective production capabilities.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 31.9% of the United States' imported finished dosage forms (FDFs) between 2020 and 2024. This dominance extends to the production of formulations containing Amikacin, where Indian manufacturers leverage extensive manufacturing capabilities and cost-effective production processes.

As of November 2024, India had 376 pharmaceutical manufacturing facilities registered with the U.S. Food and Drug Administration (FDA), including 134 dedicated to finished dosage forms. Additionally, over 800 Indian manufacturing units comply with the World Health Organization's Good Manufacturing Practices (WHO-GMP), ensuring high-quality production standards.

The cost advantages in India's pharmaceutical sector are significant, attributed to economies of scale, lower labor costs, and a well-established supply chain. These factors enable Indian manufacturers to offer Amikacin formulations at competitive prices without compromising quality.

When comparing Amikacin formulation exports, India offers a compelling balance of cost and quality. Between 2020 and 2024, India was the leading source of antibiotic finished dosage forms imported into the United States, accounting for 31.9% of the total import volume. In contrast, China contributed 6.9% during the same period.

European Union (EU) manufacturers are known for high-quality branded generics but often at higher price points. For instance, Italy accounted for 13.4% of the U.S. import volume of antibiotic FDFs between 2020 and 2024, with a higher importation cost percentage compared to India.

In Iraq, Indian pharmaceutical products are well-accepted due to their compliance with international quality standards and cost-effectiveness. The established track record of Indian manufacturers in supplying to Iraq underscores their reliability and the regulatory acceptance of their products.

The India-Iraq supply chain for Amikacin formulations has demonstrated robustness and reliability. Indian manufacturers possess substantial production capacities for finished dosage forms, supported by advanced packaging and cold chain logistics to maintain product integrity during transit.

Regulatory compliance is a cornerstone of Indian pharmaceutical manufacturing. With 134 FDA-registered finished dosage form facilities as of November 2024, Indian manufacturers adhere to stringent quality standards. Additionally, over 800 facilities comply with WHO-GMP guidelines, further ensuring product quality.

While specific data on capacity constraints or expansion plans among top Indian formulation manufacturers is limited, the consistent supply to Iraq indicates a stable production environment. Manufacturers continue to invest in facility upgrades and capacity enhancements to meet growing global demand.

For Iraqi buyers sourcing Amikacin formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. Establish clear communication with potential suppliers to understand their specific requirements and negotiate terms that align with your procurement needs.

• Payment Terms: Standard payment terms in India-Iraq pharmaceutical trade often include letters of credit (LC) or advance payments. It's essential to negotiate favorable terms that balance cash flow considerations with supplier expectations.

• Supplier Qualification Process: Implement a rigorous qualification process, including:
• Verification of regulatory approvals (e.g., FDA, WHO-GMP certifications).
• Assessment of manufacturing capabilities and quality control measures.
• Evaluation of past performance and reliability in fulfilling orders.

• Regulatory Compliance: Ensure that selected suppliers comply with both Indian and Iraqi regulatory requirements. This includes adherence to Good Manufacturing Practices (GMP) and obtaining necessary import licenses and approvals.

By adopting these strategies, Iraqi buyers can establish a reliable and cost-effective supply chain for Amikacin formulations from India.

By meticulously following these guidelines, Iraqi pharmaceutical companies can establish robust supplier relationships with Indian manufacturers, ensuring the consistent quality and safety of Amikacin formulations imported into Iraq.